Los Angeles Capital Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.95M | Buy |
36,809
+34,135
| +1,277% | +$2.81M | 0.01% | 422 |
|
|
2025
Q4 | $223K | Sell |
2,674
-92
| -3% | -$7.55K | ﹤0.01% | 1202 |
|
|
2025
Q3 | $215K | Sell |
2,766
-9,960
| -78% | -$778K | ﹤0.01% | 1250 |
|
|
2025
Q2 | $995K | Sell |
12,726
-42,334
| -77% | -$3.16M | ﹤0.01% | 640 |
|
|
2025
Q1 | $3.99M | Buy |
55,060
+52,086
| +1,751% | +$3.73M | 0.02% | 322 |
|
|
2024
Q4 | $220K | Buy |
+2,974
| New | +$208K | ﹤0.01% | 1030 |
|
|
2024
Q3 | – | Sell |
-4,094
| Closed | -$378K | – | 1206 |
|
|
2024
Q2 | $378K | Sell |
4,094
-4,326
| -51% | -$383K | ﹤0.01% | 936 |
|
|
2024
Q1 | $805K | Sell |
8,420
-59
| -0.7% | -$4.96K | ﹤0.01% | 755 |
|
|
2023
Q4 | $647K | Sell |
8,479
-103,351
| -92% | -$7.19M | ﹤0.01% | 805 |
|
|
2023
Q3 | $7.75M | Buy |
111,830
+12,216
| +12% | +$982K | 0.03% | 265 |
|
|
2023
Q2 | $9.4M | Buy |
99,614
+5,980
| +6% | +$520K | 0.04% | 267 |
|
|
2023
Q1 | $7.75M | Sell |
93,634
-3,608
| -4% | -$284K | 0.03% | 301 |
|
|
2022
Q4 | $7.26M | Sell |
97,242
-6,270
| -6% | -$483K | 0.04% | 328 |
|
|
2022
Q3 | $8.55M | Buy |
103,512
+55,291
| +115% | +$5.32M | 0.04% | 289 |
|
|
2022
Q2 | $4.58M | Buy |
48,221
+12,819
| +36% | +$1.33M | 0.02% | 377 |
|
|
2022
Q1 | $4.17M | Sell |
35,402
-74,110
| -68% | -$8.31M | 0.02% | 391 |
|
|
2021
Q4 | $14.2M | Sell |
109,512
-24,912
| -19% | -$2.91M | 0.05% | 243 |
|
|
2021
Q3 | $15.2M | Sell |
134,424
-4,066
| -3% | -$464K | 0.07% | 222 |
|
|
2021
Q2 | $14.3M | Buy |
138,490
+245
| +0.2% | +$23.1K | 0.06% | 247 |
|
|
2021
Q1 | $11.6M | Sell |
138,245
-814,073
| -85% | -$68.8M | 0.05% | 283 |
|
|
2020
Q4 | $86.9M | Sell |
952,318
-25,472
| -3% | -$2.11M | 0.37% | 57 |
|
|
2020
Q3 | $78M | Sell |
977,790
-52,647
| -5% | -$4.11M | 0.36% | 62 |
|
|
2020
Q2 | $71.2M | Buy |
1,030,437
+31,611
| +3% | +$2.25M | 0.34% | 73 |
|
|
2020
Q1 | $62.8M | Buy |
998,826
+70,437
| +8% | +$5.08M | 0.4% | 69 |
|
|
2019
Q4 | $72.2M | Sell |
928,389
-17,406
| -2% | -$1.36M | 0.36% | 77 |
|
|
2019
Q3 | $69.3M | Buy |
945,795
+357,057
| +61% | +$25.1M | 0.38% | 71 |
|
|
2019
Q2 | $36.3M | Sell |
588,738
-3,162
| -0.5% | -$191K | 0.19% | 121 |
|
|
2019
Q1 | $37.7M | Buy |
591,900
+343,980
| +139% | +$19.6M | 0.21% | 120 |
|
|
2018
Q4 | $12.7M | Sell |
247,920
-494,892
| -67% | -$25M | 0.08% | 241 |
|
|
2018
Q3 | $43.1M | Buy |
742,812
+8,880
| +1% | +$434K | 0.23% | 111 |
|
|
2018
Q2 | $35.6M | Buy |
733,932
+37,968
| +5% | +$1.77M | 0.2% | 131 |
|
|
2018
Q1 | $32.4M | Buy |
695,964
+17,205
| +3% | +$747K | 0.18% | 144 |
|
|
2017
Q4 | $25.5M | Sell |
678,759
-52,536
| -7% | -$1.93M | 0.14% | 188 |
|
|
2017
Q3 | $26.6M | Sell |
731,295
-9,372
| -1% | -$357K | 0.15% | 175 |
|
|
2017
Q2 | $29.2M | Buy |
740,667
+382,077
| +107% | +$13.9M | 0.18% | 151 |
|
|
2017
Q1 | $11.2M | Buy |
358,590
+323,307
| +916% | +$10.1M | 0.08% | 278 |
|
|
2016
Q4 | $1.1M | Buy |
+35,283
| New | +$1.14M | 0.01% | 683 |
|
|
2014
Q4 | – | Sell |
-71,820
| Closed | -$1.22M | – | 1120 |
|
|
2014
Q3 | $1.22M | Sell |
71,820
-2,665,662
| -97% | -$42.1M | 0.01% | 559 |
|
|
2014
Q2 | $39.2M | Sell |
2,737,482
-12,186
| -0.4% | -$165K | 0.38% | 72 |
|
|
2014
Q1 | $34M | Buy |
2,749,668
+676,710
| +33% | +$7.81M | 0.37% | 71 |
|
|
2013
Q4 | $22.7M | Buy |
+2,072,958
| New | +$23.4M | 0.25% | 132 |
|
|
2013
Q3 | – | Sell |
-236,010
| Closed | -$2.64M | – | 1318 |
|
|
2013
Q2 | $2.64M | Buy |
+236,010
| New | +$2.79M | 0.04% | 406 |
|
Other funds holding EW
VCM
VPM
Los Angeles Capital Management's EW Position: Q1 2026 in Review
Los Angeles Capital Management increased its Edwards Lifesciences (EW) stake by 1,277% in Q1 2026, buying an estimated $2.81M and bringing the position to 36,809 shares worth $2.95M. The position accounts for 0.01% of the portfolio, ranked #422.
Los Angeles Capital Management first reported a position in EW in Q2 2013 and has held it in 42 quarters since. The position peaked at $86.9M in Q4 2020. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Los Angeles Capital Management held 36,809 shares of Edwards Lifesciences worth $2.95M as of Q1 2026.
- Los Angeles Capital Management bought 34,135 Edwards Lifesciences shares in Q1 2026, an estimated $2.81M.
- Edwards Lifesciences made up 0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #422 holding.
- Los Angeles Capital Management first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 42 quarters since.
- Los Angeles Capital Management's Edwards Lifesciences position peaked at $86.9M in Q4 2020.
- 1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.